Hormone Therapy for Lung Cancer Frederick MD

Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found. The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

Frederick Memorial Hospital
(240) 566-3300
400 West Seventh Street
Frederick, MD
specialty
General medical surgical
Hospital Type
Nongovernment, Not-for-profit

Data Provided by:
North Springs Behav Healthcare
(703) 777-0800
42009 Victory Lane
Leesburg, VA
specialty
Psychiatric
Hospital Type
Investor-owned (for profit)
Hospital System
Psychiatric Solutions

Data Provided by:
Frederick Memorial Hospital
(301) 698-3300
400 West Seventh Street
Frederick, MD
Medicare Number
210005
Bed Count
179

Loudoun Hospital Center
(703) 858-6000
44045 Riverside Parkway
Leesburg, VA
Medicare Number
490043
Bed Count
92

Loudoun Hospital Center, Lansdowne
(703) 777-3300
44045 Riverside Parkway
Leesburg, VA
Specialty
Hospitals

Inova Loudoun Hospital
(703) 858-6000
44045 Riverside Parkway
Leesburg, VA
specialty
General medical surgical
Hospital Type
Nongovernment, Not-for-profit
Hospital System
Inova Health System

Data Provided by:
Mountain Manor Treatment Ctr
(301) 447-2361
Route 15
Emmitsburg, MD
specialty
Alcoholism/Other chemical dependancy
Hospital Type
Investor-owned (for profit)

Data Provided by:
Frederick Memorial Hospital
(301) 698-3300
400 West Seventh St
Frederick, MD
Specialty
Hospitals

Piedmont Behavioral Hlth Ctr
(703) 777-0800
42009 Victory Lane
Leesburg, VA
Medicare Number
494020
Bed Count
77

Mountain Manor Treatment Ctr
(301) 447-2361
Route 15
Emmitsburg, MD
Medicare Number
777777
Bed Count
140

Data Provided by:

Hormone Therapy for Lung Cancer

Provided By:

SATURDAY, Sept. 19 (HealthDay News) -- Taking a combination form of hormone replacement therapy, which includes both estrogen and progestin, increases a woman's risk for dying from lung cancer, a new study has found.

The finding stems from an analysis of data from the Women's Health Initiative trial on 16,608 postmenopausal women, aged 50 to 79, in the United States who had been randomly assigned to take either a once-daily tablet of 0.625 milligrams conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or a placebo.

After eight years, 73 women taking the hormone therapy and 40 women in the placebo group had died of lung cancer. That meant, according to the researchers, that women who took the drug were 71 percent more likely to die from the disease.

The study also found that women taking the hormone therapy were 28 percent more likely to be diagnosed with lung cancer, although the study noted that the finding was not statistically significant.

"Treatment with estrogen plus progestin in postmenopausal women ... increased the number of deaths from lung cancer, in particular deaths from non-small-cell lung cancer," concluded Rowan Chlebowski, of the Los Angeles Biomedical Research Institute at Harbour-UCLA Medical Center, and his colleagues.

The researchers urged that the findings "be incorporated into risk-benefit discussions with women considering combined hormone therapy, especially those with a high risk of lung cancer ... such as current smokers or long-term past smokers."

Dr. Apar Kishor Ganti, from the University of Nebraska Medical Center in Omaha, wrote in an accompanying editorial that "because the optimum safe duration of hormone-replacement therapy in terms of lung cancer survival is unclear, such therapy should probably be avoided in women at a high risk of developing lung cancer, especially those with a history of smoking."

In fact, Ganti questioned whether hormone therapy should be used at all.

"These results, along with the findings showing no protection against coronary heart disease, seriously question whether hormone-replacement therapy has any role in medicine today," he wrote. "It is difficult to presume that the benefits of routine use of such therapy for menopausal symptoms outweigh the increased risks of mortality, especially in the absence of improvement in the quality of life."

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

More information

The U.S. National Institute on Aging has more on hormones and menopause.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com